~~<i id='D31E86B2FD'><strike id='D31E86B2FD'><tt id='D31E86B2FD'><pre id='D31E86B2FD'></pre></tt></strike></i>~~

Home» knowledge» hotspot

hotspot

author：entertainment 2025-08-15 23:05:05 Page View：8

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As Taiwan prepares for anti
Next article： Alkermes shareholders re

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

JasonBuenrostroinhisHarvardlab.CourtesyJohnD.andCatherineT.MacArthurFoundationTheyoungestofthisyear’

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Review: 'Barbie' will hit you like a shot in the heart

6:22RyanGosling,left,asKenandMargotRobbieasBarbieareseeninastillfromWarnerBros.Pictures'"Barbie."Cou